As of August 22, 2022, over 80 percent of adults in Western Australia had been vaccinated with three doses of a COVID-19 vaccine. In comparison, less than 60 percent of Queensland population aged 16 years and over and received three doses of a COVID-19 vaccine.

The number of COVID-19 vaccination doses administered per 100 people in Australia rose to 243 as of Oct 27 2023. This dataset includes a chart with historical data for Australia Coronavirus Vaccination Rate.

As of August 22, 2022, around 68.8 percent of Australians aged over 16 had received a coronavirus booster vaccine or third dose. At the beginning of the year, hundreds of thousands of booster shots were being administered daily. As 2022 progressed, the number of daily booster shots gradually trended downward as the share of Australians who had received a booster shot increased.

This dataset provides values for CORONAVIRUS VACCINATION RATE reported in several countries. The data includes current values, previous releases, historical highs and record lows, release frequency, reported unit and currency.

In 2021, a survey conducted in Australia about COVID-19 vaccinations reported that about ** percent of respondents in Australia who took part in the survey were hesitant on taking the vaccine because they worried about the side effects of the vaccines or thought the vaccines were unsafe. That same year, about ** percent of respondents in Australia said they were not willing to take the COVID-19 vaccine.

Invasive meningococcal disease is a life-threatening infection preventable through vaccination. Pediatric vaccination rates have declined during the coronavirus disease 2019 (COVID-19) pandemic. This survey aimed to understand how parents’ attitudes and behaviors have changed during the pandemic with regard to immunization and, more specifically, meningococcal vaccination. An online survey was emailed to parents of eligible children 0–4 years, following the selection process from UK, France, Germany, Italy, Brazil, Argentina, and Australia; and of adolescents 11–18 years from US. Data collection took place 19 January–16 February 2021. Quotas were set to ensure a representative sample. Eleven questions relating to general perceptions around vaccination and attitudes and behaviors toward meningitis vaccination were displayed. On 4,962 parents (average 35 years) participating in the survey, most (83%) believed important for their child to continue receiving recommended vaccines during the COVID-19 pandemic. Nearly half of routine vaccine appointments were delayed or canceled due to the pandemic, and 61% of respondents were likely to have their children catch up once COVID-19 restrictions were lifted. 30% of meningitidis vaccination appointments were canceled or delayed during the pandemic, and 21% of parents did not intend to reschedule them because of lockdown/stay at home regulations, and fear of catching COVID-19 in public places. It is crucial to communicate clear instructions to health workers and the general population and to provide appropriate safety precautions in vaccination centers. This will help to maintain vaccination rates and limit infections to prevent future outbreaks. What is the context?Invasive meningococcal disease (IMD) is an uncommon infection that can lead to permanent disabilities and even death.Meningitis vaccination can prevent IMDs caused by Neisseria meningitidis.Vaccination rates have declined during the coronavirus (COVID-19) pandemic. Invasive meningococcal disease (IMD) is an uncommon infection that can lead to permanent disabilities and even death. Meningitis vaccination can prevent IMDs caused by Neisseria meningitidis. Vaccination rates have declined during the coronavirus (COVID-19) pandemic. What is new?We collected opinion of parents from the UK, France, Germany, Italy, Brazil, Argentina, Australia, and the US, to understand their attitudes and behaviors toward meningitis vaccination during the COVID-19 pandemic.Results were reviewed by health care professional experts as well as by patient authors (IMD survivors).Most (83%) of the 4,962 parents believed that it is important for their child to continue receiving recommended vaccines during the COVID-19 pandemic.Half of the scheduled appointments for meningitis vaccination were canceled or delayed during the COVID-19 pandemic, mainly due to lockdown regulations and fear of catching COVID-19.Twenty-one percent of the parents who had their child’s meningitis vaccination appointment canceled, did not intend to reschedule it. We collected opinion of parents from the UK, France, Germany, Italy, Brazil, Argentina, Australia, and the US, to understand their attitudes and behaviors toward meningitis vaccination during the COVID-19 pandemic. Results were reviewed by health care professional experts as well as by patient authors (IMD survivors). Most (83%) of the 4,962 parents believed that it is important for their child to continue receiving recommended vaccines during the COVID-19 pandemic. Half of the scheduled appointments for meningitis vaccination were canceled or delayed during the COVID-19 pandemic, mainly due to lockdown regulations and fear of catching COVID-19. Twenty-one percent of the parents who had their child’s meningitis vaccination appointment canceled, did not intend to reschedule it. What is the impact?It is crucial that clear information is communicated by health care authorities and practitioners about the availability of vaccination during pandemic and the safety precautions that are taken.Collected opinions emphasize the importance of continuing vaccinations against infectious diseases during a pandemic. It is crucial that clear information is communicated by health care authorities and practitioners about the availability of vaccination during pandemic and the safety precautions that are taken. Collected opinions emphasize the importance of continuing vaccinations against infectious diseases during a pandemic.

Context

The COVID-19 outbreak has brought the whole planet to its knees.More over 4.5 million people have died since the writing of this notebook, and the only acceptable way out of the disaster is to vaccinate all parts of society. Despite the fact that the benefits of vaccination have been proved to the world many times, anti-vaccine groups are springing up all over the world. This data set was generated to investigate the impact of coronavirus vaccinations on coronavirus mortality.

Content

Data Collection

This dataset is a combination of the following three datasets:

1.https://www.kaggle.com/gpreda/covid-world-vaccination-progress

2.https://covid19.who.int/WHO-COVID-19-global-data.csv

3.https://www.kaggle.com/rsrishav/world-population

you can find more detail about this dataset by reading this notebook:

https://www.kaggle.com/sinakaraji/simple-linear-regression-covid-vaccination

Countries in this dataset:

As of September 2021, around 62 percent of adults in Australia aged 18 to 34 years who wanted a vaccination against COVID-19 had received one, which is a much lower rate than in Canada where 95 percent of adults who wanted a vaccination had already had one. This statistic illustrates the percentage of adults aged 18 to 34 years who had been vaccinated against COVID-19 among those who wanted to get vaccinated worldwide as of September 2021, by country.

IntroductionAchieving high COVID-19 vaccine booster coverage is an ongoing global challenge. Health authorities need evidence about effective communication interventions to improve acceptance and uptake. This study aimed to test effects of persuasive messages about COVID-19 vaccine booster doses on intention to vaccinate amongst eligible adults in Australia.MethodsIn this online randomised controlled trial, adult participants received one of four intervention messages or a control message. The control message provided information about booster dose eligibility. Intervention messages added to the control message, each using a different persuasive strategy, including: emphasising personal health benefits of booster doses, community health benefits, non-health benefits, and personal agency in choosing vaccination. After the intervention, participants answered items about COVID-19 booster vaccine intention and beliefs. Intervention groups were compared to the control using tests of two proportions; differences of ≥5 percentage points were deemed clinically significant. A sub-group analysis was conducted among hesitant participants.ResultsOf the 487 consenting and randomised participants, 442 (90.8%) completed the experiment and were included in the analysis. Participants viewing messages emphasising non-health benefits had the highest intention compared to those who viewed the control message (percentage point diff: 9.0, 95% CI -0.8, 18.8, p = 0.071). Intention was even higher among hesitant individuals in this intervention group compared to the control group (percentage point diff: 15.6, 95% CI -6.0, 37.3, p = 0.150). Conversely, intention was lower among hesitant individuals who viewed messages emphasising personal agency compared to the control group (percentage point diff: -10.8, 95% CI -33.0, 11.4, p = 0.330), although evidence in support of these findings is weak.ConclusionHealth authorities should highlight non-health benefits to encourage COVID-19 vaccine booster uptake but use messages emphasising personal agency with caution. These findings can inform communication message development and strategies to improve COVID-19 vaccine booster uptake.Clinical trial registration: Registered with the Australian New Zealand Clinical Trials Registry (ACTRN12622001404718); trial webpage: https://www.anzctr.org.au/ACTRN12622001404718.aspx

Based on a comparison of coronavirus deaths in 210 countries relative to their population, Peru had the most losses to COVID-19 up until July 13, 2022. As of the same date, the virus had infected over 557.8 million people worldwide, and the number of deaths had totaled more than 6.3 million. Note, however, that COVID-19 test rates can vary per country. Additionally, big differences show up between countries when combining the number of deaths against confirmed COVID-19 cases. The source seemingly does not differentiate between "the Wuhan strain" (2019-nCOV) of COVID-19, "the Kent mutation" (B.1.1.7) that appeared in the UK in late 2020, the 2021 Delta variant (B.1.617.2) from India or the Omicron variant (B.1.1.529) from South Africa.

The difficulties of death figures

This table aims to provide a complete picture on the topic, but it very much relies on data that has become more difficult to compare. As the coronavirus pandemic developed across the world, countries already used different methods to count fatalities, and they sometimes changed them during the course of the pandemic. On April 16, for example, the Chinese city of Wuhan added a 50 percent increase in their death figures to account for community deaths. These deaths occurred outside of hospitals and went unaccounted for so far. The state of New York did something similar two days before, revising their figures with 3,700 new deaths as they started to include “assumed” coronavirus victims. The United Kingdom started counting deaths in care homes and private households on April 29, adjusting their number with about 5,000 new deaths (which were corrected lowered again by the same amount on August 18). This makes an already difficult comparison even more difficult. Belgium, for example, counts suspected coronavirus deaths in their figures, whereas other countries have not done that (yet). This means two things. First, it could have a big impact on both current as well as future figures. On April 16 already, UK health experts stated that if their numbers were corrected for community deaths like in Wuhan, the UK number would change from 205 to “above 300”. This is exactly what happened two weeks later. Second, it is difficult to pinpoint exactly which countries already have “revised” numbers (like Belgium, Wuhan or New York) and which ones do not. One work-around could be to look at (freely accessible) timelines that track the reported daily increase of deaths in certain countries. Several of these are available on our platform, such as for Belgium, Italy and Sweden. A sudden large increase might be an indicator that the domestic sources changed their methodology.

Where are these numbers coming from?

The numbers shown here were collected by Johns Hopkins University, a source that manually checks the data with domestic health authorities. For the majority of countries, this is from national authorities. In some cases, like China, the United States, Canada or Australia, city reports or other various state authorities were consulted. In this statistic, these separately reported numbers were put together. For more information or other freely accessible content, please visit our dedicated Facts and Figures page.

BackgroundAcceptability and perception of the COVID-19 vaccine among different social groups have been the subject of several studies. However, little is known about foreign medical students in Chinese universities.AimThis study, therefore, fills the literature gap using a focus group technique to assess the acceptance and perception of the COVID-19 vaccine among foreign medical students in China.MethodsThe study adopted an online cross-sectional survey method following the Chinese universities' lockdowns to collect the data between March and April 2022. A data collection questionnaire was developed, and then the link was shared with the respondents through key informants in different universities in China to obtain the data. The data collection process only included foreign medical students who were in China from May 2021 to April 2022. The authors received a total of 403 responses from the respondents. During data processing, we excluded 17 respondents since they were not in China while administering the questionnaire to enhance the data validity. The authors then coded the remaining 386 respondents for the estimation process. We finally applied the multilinear logistics regression technique to model the COVID-19 vaccine acceptance with the response or influencing factors, including the mediating factors among the foreign medical students in China.ResultsThe data statistics show that 4.9% of the respondents were younger than 20 years, 91.5% were 20–40 years old, and 3.6% were older than 40 years; 36.3% of respondents were female subjects and 63.7% were male subjects. The results also show that the respondents are from six continents, including the African continent, 72.4%, Asia 17.4%, 3.1% from Europe, 2.8% from North America, 1.6% from Australia, and 2.3% from South America. The mediation analysis for the gender variable (β = 0.235, p = 0.002) suggests that gender is a significant channel in COVID-19 vaccine acceptance and perception among foreign medical students in China. Also, the main analysis shows that opinion on the safety of the vaccine (β = 0.081, p = 0.043), doses of the vaccine to receive (β = 0.175, p = 0.001), vaccine safety with some side effects (β = 0.15, p = 0.000), and the possibility of acquiring COVID-19 after vaccination (β = 0.062, p = 0.040) are all positive factors influencing vaccine acceptability and perception. Also, the home continent (β = −0.062, p = 0.071) is a negative factor influencing COVID-19 vaccine acceptance and perception. Furthermore, the finding shows that fear perceptions has affected 200 (51.81%) respondents. The medical students feared that the vaccines might result in future implications such as infertility, impotence, and systemic health conditions such as cardiovascular, respiratory, or deep vein thrombosis. In addition, 186 (48.19%) students feared that the vaccines were intended to shorten life expectancy.ConclusionCOVID-19 vaccination acceptability and perception among medical students in China is high, most predominantly due to their knowledge of medicine composition formulation. Despite widespread acceptance by the general public and private stakeholders, we concluded that vaccination resistance remains a significant factor among medical students and trainees. The study further adds that in considering the COVID-19 vaccine, the factor of the home continent plays a significant role in vaccine hesitancy among foreign medical students. Also, knowledge, information, and education are important pillars confronting new medicine administered among medical trainees. Finally, there is a low rate of COVID-19 vaccine hesitancy among foreign medical students in China. The study, therefore, recommends targeted policy strategies, including sensitization, detailed public information, and education, especially for medical colleges and institutions on the COVID-19 vaccination, to achieve 100%. Furthermore, the study recommends that future researchers explore other factors influencing accurate information and education for successful COVID-19 vaccination implementation.

As of May 2, 2023, the outbreak of the coronavirus disease (COVID-19) had spread to almost every country in the world, and more than 6.86 million people had died after contracting the respiratory virus. Over 1.16 million of these deaths occurred in the United States.

Waves of infections Almost every country and territory worldwide have been affected by the COVID-19 disease. At the end of 2021 the virus was once again circulating at very high rates, even in countries with relatively high vaccination rates such as the United States and Germany. As rates of new infections increased, some countries in Europe, like Germany and Austria, tightened restrictions once again, specifically targeting those who were not yet vaccinated. However, by spring 2022, rates of new infections had decreased in many countries and restrictions were once again lifted.

What are the symptoms of the virus? It can take up to 14 days for symptoms of the illness to start being noticed. The most commonly reported symptoms are a fever and a dry cough, leading to shortness of breath. The early symptoms are similar to other common viruses such as the common cold and flu. These illnesses spread more during cold months, but there is no conclusive evidence to suggest that temperature impacts the spread of the SARS-CoV-2 virus. Medical advice should be sought if you are experiencing any of these symptoms.

On March 10, 2023, the Johns Hopkins Coronavirus Resource Center ceased its collecting and reporting of global COVID-19 data. For updated cases, deaths, and vaccine data please visit the following sources: World Health Organization (WHO)For more information, visit the Johns Hopkins Coronavirus Resource Center.-- Esri COVID-19 Trend Report for 3-9-2023 --0 Countries have Emergent trend with more than 10 days of cases: (name : # of active cases) 41 Countries have Spreading trend with over 21 days in new cases curve tail: (name : # of active cases)Monaco : 13, Andorra : 25, Marshall Islands : 52, Kyrgyzstan : 79, Cuba : 82, Saint Lucia : 127, Cote d'Ivoire : 148, Albania : 155, Bosnia and Herzegovina : 172, Iceland : 196, Mali : 198, Suriname : 246, Botswana : 247, Barbados : 274, Dominican Republic : 304, Malta : 306, Venezuela : 334, Micronesia : 346, Uzbekistan : 356, Afghanistan : 371, Jamaica : 390, Latvia : 402, Mozambique : 406, Kosovo : 412, Azerbaijan : 427, Tunisia : 528, Armenia : 594, Kuwait : 716, Thailand : 746, Norway : 768, Croatia : 847, Honduras : 1002, Zimbabwe : 1067, Saudi Arabia : 1098, Bulgaria : 1148, Zambia : 1166, Panama : 1300, Uruguay : 1483, Kazakhstan : 1671, Paraguay : 2080, Ecuador : 53320 Countries may have Spreading trend with under 21 days in new cases curve tail: (name : # of active cases)61 Countries have Epidemic trend with over 21 days in new cases curve tail: (name : # of active cases)Liechtenstein : 48, San Marino : 111, Mauritius : 742, Estonia : 761, Trinidad and Tobago : 1296, Montenegro : 1486, Luxembourg : 1540, Qatar : 1541, Philippines : 1915, Ireland : 1946, Brunei : 2010, United Arab Emirates : 2013, Denmark : 2111, Sweden : 2149, Finland : 2154, Hungary : 2169, Lebanon : 2208, Bolivia : 2838, Colombia : 3250, Switzerland : 3321, Peru : 3328, Slovakia : 3556, Malaysia : 3608, Indonesia : 3793, Portugal : 4049, Cyprus : 4279, Argentina : 5050, Iran : 5135, Lithuania : 5323, Guatemala : 5516, Slovenia : 5689, South Africa : 6604, Georgia : 7938, Moldova : 8082, Israel : 8746, Bahrain : 8932, Netherlands : 9710, Romania : 12375, Costa Rica : 12625, Singapore : 13816, Serbia : 14093, Czechia : 14897, Spain : 17399, Ukraine : 19568, Canada : 24913, New Zealand : 25136, Belgium : 30599, Poland : 38894, Chile : 41055, Australia : 50192, Mexico : 65453, United Kingdom : 65697, France : 68318, Italy : 70391, Austria : 90483, Brazil : 134279, Korea - South : 209145, Russia : 214935, Germany : 257248, Japan : 361884, US : 6440500 Countries may have Epidemic trend with under 21 days in new cases curve tail: (name : # of active cases) 54 Countries have Controlled trend: (name : # of active cases)Palau : 3, Saint Kitts and Nevis : 4, Guinea-Bissau : 7, Cabo Verde : 8, Mongolia : 8, Benin : 9, Maldives : 10, Comoros : 10, Gambia : 12, Bhutan : 14, Cambodia : 14, Syria : 14, Seychelles : 15, Senegal : 16, Libya : 16, Laos : 17, Sri Lanka : 19, Congo (Brazzaville) : 19, Tonga : 21, Liberia : 24, Chad : 25, Fiji : 26, Nepal : 27, Togo : 30, Nicaragua : 32, Madagascar : 37, Sudan : 38, Papua New Guinea : 38, Belize : 59, Egypt : 60, Algeria : 64, Burma : 65, Ghana : 72, Haiti : 74, Eswatini : 75, Guyana : 79, Rwanda : 83, Uganda : 88, Kenya : 92, Burundi : 94, Angola : 98, Congo (Kinshasa) : 125, Morocco : 125, Bangladesh : 127, Tanzania : 128, Nigeria : 135, Malawi : 148, Ethiopia : 248, Vietnam : 269, Namibia : 422, Cameroon : 462, Pakistan : 660, India : 4290 41 Countries have End Stage trend: (name : # of active cases)Sao Tome and Principe : 1, Saint Vincent and the Grenadines : 2, Somalia : 2, Timor-Leste : 2, Kiribati : 8, Mauritania : 12, Oman : 14, Equatorial Guinea : 20, Guinea : 28, Burkina Faso : 32, North Macedonia : 351, Nauru : 479, Samoa : 554, China : 2897, Taiwan* : 249634 -- SPIKING OF NEW CASE COUNTS --20 countries are currently experiencing spikes in new confirmed cases:Armenia, Barbados, Belgium, Brunei, Chile, Costa Rica, Georgia, India, Indonesia, Ireland, Israel, Kuwait, Luxembourg, Malaysia, Mauritius, Portugal, Sweden, Ukraine, United Kingdom, Uzbekistan 20 countries experienced a spike in new confirmed cases 3 to 5 days ago: Argentina, Bulgaria, Croatia, Czechia, Denmark, Estonia, France, Korea - South, Lithuania, Mozambique, New Zealand, Panama, Poland, Qatar, Romania, Slovakia, Slovenia, Switzerland, Trinidad and Tobago, United Arab Emirates 47 countries experienced a spike in new confirmed cases 5 to 14 days ago: Australia, Austria, Bahrain, Bolivia, Brazil, Canada, Colombia, Congo (Kinshasa), Cyprus, Dominican Republic, Ecuador, Finland, Germany, Guatemala, Honduras, Hungary, Iran, Italy, Jamaica, Japan, Kazakhstan, Lebanon, Malta, Mexico, Micronesia, Moldova, Montenegro, Netherlands, Nigeria, Pakistan, Paraguay, Peru, Philippines, Russia, Saint Lucia, Saudi Arabia, Serbia, Singapore, South Africa, Spain, Suriname, Thailand, Tunisia, US, Uruguay, Zambia, Zimbabwe 194 countries experienced a spike in new confirmed cases over 14 days ago: Afghanistan, Albania, Algeria, Andorra, Angola, Antigua and Barbuda, Argentina, Armenia, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Brunei, Bulgaria, Burkina Faso, Burma, Burundi, Cabo Verde, Cambodia, Cameroon, Canada, Central African Republic, Chad, Chile, China, Colombia, Comoros, Congo (Brazzaville), Congo (Kinshasa), Costa Rica, Cote d'Ivoire, Croatia, Cuba, Cyprus, Czechia, Denmark, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Eswatini, Ethiopia, Fiji, Finland, France, Gabon, Gambia, Georgia, Germany, Ghana, Greece, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, Korea - South, Kosovo, Kuwait, Kyrgyzstan, Laos, Latvia, Lebanon, Lesotho, Liberia, Libya, Liechtenstein, Lithuania, Luxembourg, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia, Moldova, Monaco, Mongolia, Montenegro, Morocco, Mozambique, Namibia, Nauru, Nepal, Netherlands, New Zealand, Nicaragua, Niger, Nigeria, North Macedonia, Norway, Oman, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russia, Rwanda, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Samoa, San Marino, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Seychelles, Sierra Leone, Singapore, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Sudan, Spain, Sri Lanka, Sudan, Suriname, Sweden, Switzerland, Syria, Taiwan*, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Turkey, Tuvalu, US, Uganda, Ukraine, United Arab Emirates, United Kingdom, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, West Bank and Gaza, Yemen, Zambia, Zimbabwe Strongest spike in past two days was in US at 64,861 new cases.Strongest spike in past five days was in US at 64,861 new cases.Strongest spike in outbreak was 424 days ago in US at 1,354,505 new cases. Global Total Confirmed COVID-19 Case Rate of 8620.91 per 100,000Global Active Confirmed COVID-19 Case Rate of 37.24 per 100,000Global COVID-19 Mortality Rate of 87.69 per 100,000 21 countries with over 200 per 100,000 active cases.5 countries with over 500 per 100,000 active cases.3 countries with over 1,000 per 100,000 active cases.1 country with over 2,000 per 100,000 active cases.Nauru is worst at 4,354.54 per 100,000.

BackgroundEncephalitis, an inflammatory central nervous system disease causing significant morbidity and mortality, disproportionately affects low- and middle-income countries (LMICs) due to healthcare disparities. Encephalitis has diverse etiologies—viral, autoimmune, bacterial, parasitic—each with distinct clinical and epidemiological features. Despite declining global age-standardized rates since 1990, inequities in diagnostics, vaccine coverage, and critical care persist, worsened by COVID-19 pandemic, which delayed diagnoses and disrupted vaccinations.MethodsUsing Global Burden of Disease (GBD) 2021 data, we analyzed age-standardized prevalence, incidence, mortality, and disability-adjusted life-years (DALYs) across 204 countries (1990–2021). We used the Bayesian Age-Period-Cohort model with integrated nested Laplace approximation to predict encephalitis’ future trends, through 2040, enhancing the study’s predictive value. Sociodemographic Index (SDI) stratification and Bayesian meta-regression models assessed trends, with significance determined via 95% uncertainty intervals and estimated annual percentage change (EAPC).ResultsIn 2021, 4.64 million individuals worldwide were affected by encephalitis (1.49 million new cases; 92,000 deaths), encompassing cases spanning acute, subacute, and chronic stages of the disease. Low-middle SDI regions bore 3–5 times higher burdens than high-SDI regions. South Asia had the highest burden (age-standardized prevalence rate [ASPR]: 140.9/100,000; incidence [ASIR]: 51.3/100,000), while Australasia reported the lowest (ASPR: 1.94/100,000). High-SDI countries showed distinct patterns, such as rising incidence in Australia. COVID-19 was associated with an 18% increase in DALYs in high-burden regions. National disparities were stark: Pakistan, India, and Nepal had the highest burdens; Canada, the lowest. The encephalitis burden was greater in children than in other age groups.ConclusionThis analysis advances prior GBD research by integrating post-COVID-19 insights and future burden forecasts, filling pre-pandemic study gaps. GBD dataset does not differentiate etiological subtypes, limiting our analysis granularity given encephalitis’ clinical and epidemiological heterogeneity. Socioeconomic inequities drive encephalitis burden, necessitating targeted interventions: scaling Japanese encephalitis vaccination in South Asia, strengthening African diagnostic hubs, and integrating climate-resilient surveillance. Post-pandemic recovery must prioritize healthcare infrastructure, telehealth, and policies addressing poverty and education. Global collaboration is critical to mitigate disparities and optimize region-specific strategies.

From 20 October 2023, COVID-19 datasets will no longer be updated. Detailed information is available in the fortnightly NSW Respiratory Surveillance Report: https://www.health.nsw.gov.au/Infectious/covid-19/Pages/reports.aspx. Latest national COVID-19 spread, vaccination and treatment metrics are available on the Australian Government Health website: https://www.health.gov.au/topics/covid-19/reporting?language=und

The data is for locations associated with confirmed COVID-19 cases that have been classified by NSW Health for action. Refer to the latest COVID-19 news and updates for information on action advice provided by NSW Health.

From Monday 15 November 2021, NSW Health will no longer list case locations that a COVID-19 positive person has attended. This is due to a number of reasons, including high vaccination rates in the community. If you are told to self-isolate by NSW Health or get tested for COVID-19 at any time you must follow this advice.

This dataset provides COVID-19 case locations by date of known outbreak, location, address and action. This data is subject to change as further locations are identified. Locations are removed when 14 days have passed since the last known date that a confirmed case was associated with the location.

The Government has obligations under the Privacy and Personal Information Protection Act 1998 and the Health Records and Information Privacy Act 2002 in relation to the collection, use and disclosure of the personal, including the health information, of individuals. Information about NSW Privacy laws is available here: https://data.nsw.gov.au/understand-key-data-legislation.

The information collected about confirmed case locations does not include any information to directly identify individuals, such as their name, date of birth or address.

Other governments and private sector bodies also have legal obligations in relation to the protection of personal, including health, information. The Government does not authorise any reproduction or visualisation of the data on this website which includes any representation or suggestion in relation to the personal or health information of any individual. The Government does not endorse or control any third party websites including products and services offered by, from or through those websites or their content.

For any further enquiries, please contact us on datansw@customerservice.nsw.gov.au